AKT2 (E17K)
Sign in to save this workspaceAKT2 · Variant type: point · HGVS: p.E17K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Capivasertib | 97.4% | 2.6% | 96.48 |
| 2 | Brigatinib | 22.0% | 78.0% | 82.96 |
| 3 | Pemigatinib | 15.4% | 84.6% | 98.23 |
| 4 | Idelalisib | 10.9% | 89.1% | 100.00 |
| 5 | Sorafenib | 9.2% | 90.8% | 96.72 |
| 6 | Selumetinib | 7.7% | 92.3% | 100.00 |
| 7 | Remibrutinib | 6.2% | 93.8% | 99.50 |
| 8 | Tucatinib | 6.1% | 93.9% | 99.75 |
| 9 | Asciminib | 5.1% | 94.9% | 100.00 |
| 10 | Tivozanib | 5.0% | 95.0% | 92.42 |
| 11 | Pexidartinib | 4.7% | 95.3% | 99.49 |
| 12 | Osimertinib | 4.6% | 95.4% | 97.24 |
| 13 | Tepotinib | 4.6% | 95.4% | 99.75 |
| 14 | Ripretinib | 4.5% | 95.5% | 92.95 |
| 15 | Futibatinib | 4.2% | 95.8% | 98.48 |
| 16 | Alpelisib | 4.0% | 96.0% | 97.22 |
| 17 | Darovasertib | 3.8% | 96.2% | 96.99 |
| 18 | Repotrectinib | 3.7% | 96.3% | 84.21 |
| 19 | Pacritinib | 3.7% | 96.3% | 88.64 |
| 20 | Capmatinib | 3.2% | 96.8% | 99.75 |
| 21 | Abrocitinib | 3.2% | 96.8% | 99.50 |
| 22 | Mobocertinib | 3.1% | 96.9% | 97.22 |
| 23 | Palbociclib | 2.7% | 97.3% | 98.75 |
| 24 | Erdafitinib | 2.6% | 97.4% | 95.71 |
| 25 | Avapritinib | 2.6% | 97.4% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Capivasertib | 97.4% | 95.3% | +2.1% |
| Brigatinib | 22.0% | 7.1% | +14.8% |
| Pemigatinib | 15.4% | — | — |
| Idelalisib | 10.9% | — | — |
| Sorafenib | 9.2% | — | — |
| Selumetinib | 7.7% | — | — |
| Remibrutinib | 6.2% | — | — |
| Tucatinib | 6.1% | — | — |
| Asciminib | 5.1% | — | — |
| Tivozanib | 5.0% | — | — |
| Pexidartinib | 4.7% | — | — |
| Osimertinib | 4.6% | — | — |
| Tepotinib | 4.6% | 11.5% | -6.9% |
| Ripretinib | 4.5% | — | — |
| Futibatinib | 4.2% | — | — |
| Alpelisib | 4.0% | — | — |
| Darovasertib | 3.8% | — | — |
| Repotrectinib | 3.7% | — | — |
| Pacritinib | 3.7% | — | — |
| Capmatinib | 3.2% | — | — |
| Abrocitinib | 3.2% | — | — |
| Mobocertinib | 3.1% | — | — |
| Palbociclib | 2.7% | — | — |
| Erdafitinib | 2.6% | — | — |
| Avapritinib | 2.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
| carcinoma_urinary_tract | Bladder | ref |
| carcinoma_breast | Breast | ref |
| carcinoma_thyroid | Thyroid | ref |
| carcinoma_upper_aerodigestive_tract | Brain/CNS | ref |
| BRCA-EU | Breast | ref |
| BRCA-UK | Breast | ref |
| LUSC-US | Lung | ref |
| SKCA-BR | Skin | ref |
| THCA-US | Thyroid | ref |
| LUSC | Lung | ref |
| THCA | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.4ms